Differences in the genomic profiles of cell‐free DNA between plasma, sputum, urine, and tumor tissue in advanced NSCLC
Published 2019 View Full Article
- Home
- Publications
- Publication Search
- Publication Details
Title
Differences in the genomic profiles of cell‐free DNA between plasma, sputum, urine, and tumor tissue in advanced NSCLC
Authors
Keywords
-
Journal
Cancer Medicine
Volume 8, Issue 3, Pages 910-919
Publisher
Wiley
Online
2019-02-15
DOI
10.1002/cam4.1935
References
Ask authors/readers for more resources
Related references
Note: Only part of the references are listed.- Investigating Novel Resistance Mechanisms to Third-Generation EGFR Tyrosine Kinase Inhibitor Osimertinib in Non–Small Cell Lung Cancer Patients
- (2018) Zhe Yang et al. CLINICAL CANCER RESEARCH
- Impact of Concurrent Genomic Alterations Detected by Comprehensive Genomic Sequencing on Clinical Outcomes in East-Asian Patients with EGFR-Mutated Lung Adenocarcinoma
- (2018) Seijiro Sato et al. Scientific Reports
- Quantification of plasma EGFR mutations in patients with lung cancers: Comparison of the performance of ARMS-Plus and droplet digital PCR
- (2017) Lin Wang et al. LUNG CANCER
- Cell-Free DNA from Ascites and Pleural Effusions: Molecular Insights into Genomic Aberrations and Disease Biology
- (2017) Hatim Husain et al. MOLECULAR CANCER THERAPEUTICS
- Evolution and clinical impact of co-occurring genetic alterations in advanced-stage EGFR-mutant lung cancers
- (2017) Collin M Blakely et al. NATURE GENETICS
- Association of mutant EGFR L858R and exon 19 concentration in circulating cell-free DNA using droplet digital PCR with response to EGFR-TKIs in NSCLC
- (2017) Yan-Juan Zhu et al. Oncology Letters
- Cross-Platform Comparison of Four Leading Technologies for Detecting EGFR Mutations in Circulating Tumor DNA from Non-Small Cell Lung Carcinoma Patient Plasma
- (2017) Ting Xu et al. Theranostics
- Circulating tumor DNA identified by targeted sequencing in advanced-stage non-small cell lung cancer patients
- (2016) Song Xu et al. CANCER LETTERS
- Urinary circulating DNA detection for dynamic tracking of EGFR mutations for NSCLC patients treated with EGFR-TKIs
- (2016) S. Chen et al. Clinical & Translational Oncology
- A Highly Sensitive and Quantitative Test Platform for Detection of NSCLC EGFR Mutations in Urine and Plasma
- (2016) Karen L. Reckamp et al. Journal of Thoracic Oncology
- A gene expression signature of retinoblastoma loss-of-function is a predictive biomarker of resistance to palbociclib in breast cancer cell lines and is prognostic in patients with ER positive early breast cancer
- (2016) Luca Malorni et al. Oncotarget
- Prospective Validation of Rapid Plasma Genotyping for the Detection ofEGFRandKRASMutations in Advanced Lung Cancer
- (2016) Adrian G. Sacher et al. JAMA Oncology
- Bias-Corrected Targeted Next-Generation Sequencing for Rapid, Multiplexed Detection of Actionable Alterations in Cell-Free DNA from Advanced Lung Cancer Patients
- (2015) C. P. Paweletz et al. CLINICAL CANCER RESEARCH
- Novel Biomarker Signature That May Predict Aggressive Disease in African American Men With Prostate Cancer
- (2015) Kosj Yamoah et al. JOURNAL OF CLINICAL ONCOLOGY
- Acquired EGFR C797S mutation mediates resistance to AZD9291 in non–small cell lung cancer harboring EGFR T790M
- (2015) Kenneth S Thress et al. NATURE MEDICINE
- AZD9291 in EGFR Inhibitor–Resistant Non–Small-Cell Lung Cancer
- (2015) Pasi A. Jänne et al. NEW ENGLAND JOURNAL OF MEDICINE
- Beyond Histology: Translating Tumor Genotypes into Clinically Effective Targeted Therapies
- (2014) C. B. Meador et al. CLINICAL CANCER RESEARCH
- A Prospective, Molecular Epidemiology Study of EGFR Mutations in Asian Patients with Advanced Non–Small-Cell Lung Cancer of Adenocarcinoma Histology (PIONEER)
- (2014) Yuankai Shi et al. Journal of Thoracic Oncology
- Feasibility and clinical impact of re-biopsy in advanced non small-cell lung cancer: A prospective multicenter study in a real-world setting (GFPC study 12-01)
- (2014) Christos Chouaid et al. LUNG CANCER
- Next-generation sequencing for lung cancer
- (2013) Kehua Wu et al. Future Oncology
- EGFR mutation analysis in sputum of lung cancer patients: A multitechnique study
- (2013) A. Jasmijn Hubers et al. LUNG CANCER
- Prolonged sampling of spontaneous sputum improves sensitivity of hypermethylation analysis for lung cancer
- (2012) A Jasmijn Hubers et al. JOURNAL OF CLINICAL PATHOLOGY
- Epidermal Growth Factor Receptor Mutation Status in Circulating Free DNA in Serum: From IPASS, a Phase III Study of Gefitinib or Carboplatin/Paclitaxel in Non-small Cell Lung Cancer
- (2011) Koichi Goto et al. Journal of Thoracic Oncology
- Erlotinib versus chemotherapy as first-line treatment for patients with advanced EGFR mutation-positive non-small-cell lung cancer (OPTIMAL, CTONG-0802): a multicentre, open-label, randomised, phase 3 study
- (2011) Caicun Zhou et al. LANCET ONCOLOGY
- Gefitinib or Carboplatin–Paclitaxel in Pulmonary Adenocarcinoma
- (2009) Tony S. Mok et al. NEW ENGLAND JOURNAL OF MEDICINE
- Can free DNA be detected in sputum of lung cancer patients?
- (2008) M.A. van der Drift et al. LUNG CANCER
Publish scientific posters with Peeref
Peeref publishes scientific posters from all research disciplines. Our Diamond Open Access policy means free access to content and no publication fees for authors.
Learn MoreAsk a Question. Answer a Question.
Quickly pose questions to the entire community. Debate answers and get clarity on the most important issues facing researchers.
Get Started